More than 250 vaccines are in development, for diseases including cancers, allergies and Alzheimer’s.1

Pharmaceutical companies are innovating for the next generation of vaccines with more than 250 vaccines2 in development for the prevention or treatment of disease.

New technologies are also helping the pharmaceutical industry to find potential new vaccines.

Pipeline vaccines

74% of the COVID-19 vaccines in clinical trials are being developed by the pharmaceutical industry.3

Biopharmaceutical companies have deep scientific knowledge gained from decades of virus research, which is helping dramatically improve the chances of developing an effective vaccine for COVID-19.4

69 vaccines are in Phase III development, including 10 for cancer. 2

Over 250 vaccines are in development for the prevention or treatment of disease across all phases of the research development cycle.1

Breast cancer

Breast cancer is the most common cancer in the UK, accounting for 15% of all new cancer cases in 2016. A vaccine is currently in phase III trials and if successful it would improve the quality and length of life for patients and reduce the burden on the UK healthcare system.3

Alzheimer's

Breast cancer is the most common cancer in the UK, accounting for 15% of all new cancer cases in 2016. A vaccine is currently in phase III trials and if successful it would improve the quality and length of life for patients and reduce the burden on the UK healthcare system.3

HIV

HIV is a chronic and manageable disease. Advances in medicine have improved survival rates substantially over the past two decades. A new vaccine is currently in phase III trials and if successful it would help to reduce levels of anxiety and depression in patients and have broader benefits on employment rates and longer lives.

Cutting edge technology

Advances in our understanding of disease coupled with scientific and technological progress are helping the pharmaceutical industry to design more effective vaccines, ones with a better immune response or vaccines that can be easier or quicker to manufacture.

At the cutting-edge of vaccines development, researchers are looking at:

Spread the facts

What technology might help us beat COVID-19?

The global vaccine R&D effort in response to the COVID-19 pandemic has been unprecedented in terms of scale and speed.

The pharmaceutical industry is playing a critical role in research, development and manufacturing.  

A range of cutting edge technologies are being used to help speed up the process while maintaining levels of safety:

Whole-pathogen viruses

Viral vector technology

Nucleic Acid vaccines

Other vaccines

References

  1. PhRMA, New Era of Medicine: Vaccines, 2020
  2. OHE, Realising the Value of Vaccines in the UK: OHE Consulting Report, 2020
  3. Internal ABPI analysis of the WHO draft vaccine landscape, accessed 2nd October
  4. ABPI, Coronavirus Rolling Brief, Aug 2020